spacer
home > ebr > autumn 2018 > candidate selection
PUBLICATIONS
European Biopharmaceutical Review

Candidate Selection

In recent years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. In addition to CTLA-4 and PD-1 blockade, a wide range of therapeutics with the potential to reverse the tumour-induced suppression are under development. Despite the first successes, only a relatively small portion of patients benefit from these treatments, and it has been shown that combination therapies can improve the outcome. Today, over a thousand trials of immune checkpoints are running, resulting in some critical questions, such as:

• Are combinations being tested too quickly and that might never work
• Is the workload being doubled and efforts and chances of patients to participate in the most promising trials being wasted

Early evaluation of the effectiveness of candidate therapeutics and combination therapies can be done using mouse models and in vitro bioassays with primary mouse or human immune cells. Also, a better understanding of the tumour microenvironment and the steps needed to generate an anti-tumour response by the immune system will help design clinical trials and, ultimately, discover relevant biomarkers. Finally, dealing with the potential unwanted immunogenicity of oncology drugs is important, as the development of anti-drug antibodies (ADA) might lead to an altered efficacy and potency and autoimmune responses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thibault Janss holds a master’s degree in biochemistry, molecular, and cellular biology from the University of Liège, Belgium. Thibault received his PhD at the Grappe Interdisciplinaire de Génoprotéomique Appliquée in Liège, where he acquired a strong experience in the immunology field, working on dendritic cells and T-cell interactions. During this period, Thibault also developed an in-depth knowledge of flow cytometry. He joined ImmunXperts as a Senior Scientist at the beginning of 2017.

Sofie Pattijn is the Chief Technology Officer and Founder at ImmunXperts, and has over 20 years of experience in the field of immunogenicity assessment and in vitro assay development. Sofie has extensive hands-on lab experience and has managed and coached several in vitro teams over the last decade. From 2008 until 2013, she was Head of the in vitro immunogenicity group at AlgoNomics and Lonza Applied Protein Services. Prior to that, Sofie worked at Innogenetics for over 15 years.
spacer
Thibault Janss
spacer
spacer
spacer
Sofie Pattijn
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement